01
Clinical
A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer
Peking University Third Hospital is preparing a not-yet-recruiting dose-escalation study for YS247, a tumor neoantigen-pulsed autologous dendritic cell injection. The trial will evaluate safety, tolerability, and preliminary efficacy in participants with HRD-negative epithelial ovarian cancer.